Elo Mutual Pension Insurance Co Grows Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Elo Mutual Pension Insurance Co lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 32.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,225 shares of the biopharmaceutical company’s stock after acquiring an additional 11,089 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Royalty Pharma were worth $1,154,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Royalty Pharma by 0.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 256,189 shares of the biopharmaceutical company’s stock worth $6,620,000 after acquiring an additional 835 shares during the period. Korea Investment CORP increased its stake in shares of Royalty Pharma by 43.8% during the fourth quarter. Korea Investment CORP now owns 224,272 shares of the biopharmaceutical company’s stock worth $5,721,000 after purchasing an additional 68,300 shares in the last quarter. Fox Run Management L.L.C. raised its position in shares of Royalty Pharma by 41.3% during the 4th quarter. Fox Run Management L.L.C. now owns 55,062 shares of the biopharmaceutical company’s stock worth $1,405,000 after purchasing an additional 16,084 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Royalty Pharma in the 4th quarter valued at about $3,145,000. Finally, Hillsdale Investment Management Inc. boosted its holdings in Royalty Pharma by 2.5% in the 4th quarter. Hillsdale Investment Management Inc. now owns 24,250 shares of the biopharmaceutical company’s stock worth $619,000 after buying an additional 600 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Down 0.9 %

Shares of Royalty Pharma stock opened at $31.37 on Monday. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The stock has a market cap of $18.08 billion, a P/E ratio of 21.63, a P/E/G ratio of 2.31 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock’s 50 day simple moving average is $32.44 and its 200-day simple moving average is $28.86.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Analysts predict that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.81%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of research analyst reports. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup restated a “buy” rating on shares of Royalty Pharma in a report on Friday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and an average price target of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.